JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Machine Learning, Multi-Omics, and Digital Twin Systems for the Treatment and Management of Diabetes

Syed Afzal Uddin Biyabani*[1], Zunera Fatima[1], Pooja V Salimath[2], Vanishree P Babladi[2], Hafsa Naema[2], Sachin Patil[3]

[1]*Department of Pharmacy Practice, Deccan School of Pharmacy, Hyderabad, Telangana, India*
[2]*Department of Pharmacy Practice, Matoshree Taradevi Rampure Institute of Pharmaceutical Sciences, Kalaburagi, Karnataka, India*
[3]*Faculty of Pharmaceutical Sciences, Sharnbasva University, Kalaburagi. Karnataka, India*

Publication history: Received on 7th April 2026; Revised on 14th May 2026; Accepted on 15th May 2026

Article DOI: 10.69613/38hmat07

Abstract: Diabetes mellitus is regarded as a primary driver of global morbidity and mortality, characterized by profound metabolic heterogeneity that eludes conventional, standardized treatment protocols. Traditional care models, heavily anchored on periodic glycated hemoglobin measurements, fail to capture the highly dynamic and multi-faceted nature of the disease, leading to delayed therapeutic adjustments and sub-optimal long-term outcomes. Modern advancements at the intersection of computational intelligence, multi-omics, and digital health technologies are driving a fundamental reorganization of metabolic disease management. Machine learning models now allow the accurate forecasting of acute glycaemic excursions, personalizing therapeutic interventions before adverse events occur by utilizing high-frequency data streams from continuous glucose monitors, wearable biosensors, and clinical registries. Simultaneously, genomic, transcriptomic, proteomic, and metabolomic profiling have unveiled distinct biological subphenotypes, enabling the targeted matching of pharmacotherapies to individual metabolic signatures. This systems-level approach is further operationalized through automated closed-loop insulin delivery networks and digital twin system that replicate human metabolic physiology *in silico*. The unification of these technologies shifts metabolic medicine from a historical, reactive discipline into a continuous, predictive, and highly individualised science. The convergence of computational biology, real-time sensing, and multi-omic stratification provides a robust framework to mitigate microvascular and macrovascular complications, optimize therapeutic adherence, and establish a scalable model for personalized endocrinology worldwide.

Keywords: Personalized Medicine; Machine Learning; Closed-Loop Systems; Multi-Omics Stratification; Digital Twins.

1. Introduction

Diabetes mellitus is one of the most formidable public health challenges of the twenty-first century, characterized by chronic hyperglycemia stemming from absolute or relative deficiencies in insulin secretion, action, or both [1]. The global prevalence of this metabolic disorder has risen dramatically over the past several decades, driven by rapid urbanization, sedentary lifestyles, dietary transitions, and complex genetic predispositions [2]. While therapeutic choices have expanded to include advanced insulin analogs, glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors, clinical outcomes remain highly variable across patient populations [3]. This discrepancy highlights the major shortcomings of traditional, population-level treatment models, which frequently fail to account for individual variations in pathophysiology, therapeutic response, and disease progression rates. Historically, clinical management has relied on the measurement of glycated hemoglobin (HbA1c) as the gold standard for assessing long-term glycaemic control and predicting the risk of microvascular and macrovascular complications [4]. However, HbA1c is a retrospective, retrospective average metric that fails to capture acute, daily glycaemic excursions, including severe, transient hypoglycaemia and postprandial hyper-glycaemic spikes [5]. These short-term fluctuations, quantified through metrics like time-in-range (TIR) and glycaemic variability (GV), are increasingly recognized as independent drivers of oxidative stress, endothelial dysfunction, and accelerated vascular damage [6]. A critical clinical need exists to transition from episodic, glucocentric monitoring to a continuous, proactive, and multi-dimensional care model capable of resolving the biological and behavioral nuances of each patient.

The intersection of artificial intelligence (AI), multi-omics profiling, and digital health technology offers a highly scalable framework to resolve these limitations [7]. High-performance machine learning algorithms, including deep recurrent neural networks and transformer-based systems, can process massive streams of physiological data from continuous glucose monitoring (CGM) systems, wearable physical activity trackers, and digital insulin delivery devices [8]. This computational capacity allows for real-time risk

---

* Corresponding author: Syed Afzal Uddin Biyabani

forecasting, automated insulin titration, and individualized clinical decision support [9]. Molecular profiling via genomics, transcriptomics, proteomics, and metabolomics has revealed that diabetes is not a simple binary classification of type 1 and type 2, but rather a complex spectrum of distinct biological subphenotypes with unique disease trajectories and therapeutic sensitivities [10].

The current medicine must adopt a systems biology perspective that views diabetes as an emergent property of interconnected biochemical, cellular, and physiological networks to fully utilize these innovations[11]. This approach combines molecular data with real-time digital phenotyping to construct dynamic, computational representations of a patient's metabolic state, often referred to as a "metabolic digital twin" [12]. This review traces the transition from conventional, reactive care algorithms to proactive, systems-based precision diabetology, highlighting the computational mechanisms, clinical outcomes, and biological dimensions that define this digital transformation

2. Shift from Conventional Management to Proactive, Systems-Based Diabetology

2.1. Limitations of Standardized Glucocentric Algorithms

2.1.1. Chronic Delayed Therapeutic Titration

Conventional diabetes care models are structurally episodic, relying on quarterly or bi-annual outpatient clinic visits to evaluate glycaemic control and adjust pharmacotherapeutic regimens [13]. This clinical design introduces a structural delay in therapy optimization, commonly referred to as therapeutic inertia. Because clinicians lack continuous visibility into the patient's daily physiological fluctuations, medication adjustments are frequently delayed for months or even years, exposing the patient to prolonged periods of sub-optimal glycaemic control and increasing the cumulative risk of irreversible microvascular and macrovascular complications [14].

2.1.2. Insufficient Characterization of Glycaemic Variability

The reliance on HbA1c as the primary biomarker of glycaemic control hides critical physiological patterns [15]. Two patients with identical HbA1c values of 7.0% can present profoundly different glycaemic profiles. One patient may experience stable, narrow glucose fluctuations, while the other may suffer from frequent, severe hypoglycaemic dips and extreme postprandial hyperglycaemic spikes. Standard laboratory assessments fail to capture these volatile swings, which contribute directly to oxidative cell injury and vascular endothelial inflammation, while also raising the risk of acute, life-threatening cardiac arrhythmias during nocturnal hypoglycaemic events [16].

2.1.3. Homogenization of Heterogeneous Pathophysiologies

Traditional clinical guidelines categorize diabetes into rigid classes: type 1, type 2, gestational, and monogenic forms [17]. This categorization glosses over the vast physiological heterogeneity within these populations. For example, individuals diagnosed with type 2 diabetes exhibit wide variations in the degree of pancreatic beta-cell impairment, peripheral insulin resistance, hepatic glucose overproduction, and visceral adiposity. Applying a standardized, step-wise pharmacotherapy algorithm typically initiating metformin followed by empiric additions of secondary agents leads to highly unpredictable clinical responses, high rates of adverse drug events, and poor patient compliance [18].

2.2. Core Dimensions of Proactive Systems-Based Diabetology

2.2.1. Multi-Sensor Integration and Predictive Closed-Loop Systems

Transitioning to proactive management requires the deployment of continuous, interconnected sensing networks. The computational platform constructs a continuous multi-sensor feed of the patient's physiological state by combining real-time glucose data from subcutaneous CGM sensors with physical activity, heart rate, and sleep architecture data from wearable accelerometers and photoplethysmography sensors [19]. This high-resolution dataset feeds directly into predictive neural networks that anticipate glycaemic excursions up to several hours in advance. This capability enables automated closed-loop systems to adjust basal insulin infusion rates dynamically, preventing both hyperglycaemic spikes and hypoglycaemic nadirs before they occur physically [20].

2.2.2. Real-Time Longitudinal Metabolic Mapping

Proactive systems-based care relies on constructing a longitudinal, multi-dimensional view of a patient’s unique physiological behavior over time [21]. Instead of relying on static, historical averages, cloud-based analytics platforms continuously process incoming sensor data to calculate real-time metrics, including Time in Range (TIR), Time Above Range (TAR), Time Below Range

(TBR), and the Coefficient of Variation (CV). This real-time metabolic mapping allows algorithms to detect subtle shifts in insulin sensitivity, physical stress, or infectious prodromes, prompting timely, automated micro-adjustments to therapy and bypassing the delays inherent in traditional clinical schedules [22].

Table 1. Conventional Reactive Protocols vs. Proactive Systems-Based Diabetology

Evaluation Metric	Conventional Reactive Protocol	Proactive Systems-Based Diabetology
Data Acquisition Frequency	Episodic (typically quarterly or bi-annual venous sampling).	High-frequency continuous streams (sub-minute to 5-minute sampling rates).
Primary Clinical Biomarker	Static Glycated Hemoglobin (HbA_{1c}).	Dynamic Time in Range (TIR), Glycaemic Variability (GV), Coefficient of Variation (CV).
Clinical Decision Horizon	Retrospective (adjustments made based on historical averages over 90 days).	Real-time and Predictive (forecasting trajectories up to 60–120 minutes in advance).
Therapeutic Titration Lag	High (therapeutic inertia leading to months or years of delayed adjustments).	Sub-hourly (automated algorithmic micro-adjustments or real-time clinical alerts).
Patient Stratification	Standardized, broad categorization (Type 1 vs. Type 2 DM).	Multi-dimensional clustering based on genomic, multi-omic, and physiological digital twins.
Delivery Framework	Standardized, manual step-wise pharmacotherapy.	Autonomous multi-loop closed-loop systems and personalized adaptive regimens.



Figure 1. Multi-Sensor Data-Driven Precision Diabetology

3. Artificial Intelligence and Machine Learning in Precision Glycaemic Control

3.1. Predictive Glycaemic Modeling and Analytics

3.1.1. Deep Learning Approaches for Hypoglycaemic Forecasting

Predicting hypoglycaemic events, particularly during sleep, represents a critical safety priority in diabetes management [23]. Deep learning models, specifically Long Short-Term Memory (LSTM) networks and Gated Recurrent Units (GRUs), are uniquely suited for this task due to their capacity to capture long-term temporal dependencies in sequential, time-series data [24]. These recurrent architectures ingest history profiles containing historical CGM readings, carbohydrate ingestion logs, physical exertion levels, and insulin dosing history to project future interstitial glucose trajectories. Advanced models have indicated high sensitivity and specificity in predicting hypoglycaemia up to 60 minutes in advance, giving patients and caregivers sufficient lead time to take preventive action and avoid cognitive impairment or loss of consciousness [25].

3.1.2. Autoregressive Models for Postprandial Excursion Projection

Accurately predicting postprandial glucose excursions is difficult because of the complex interactions between meal composition, gastric emptying rates, baseline insulin sensitivity, and circulating active insulin [26]. To address these variables, hybrid autoregressive models integrate physical models of carbohydrate digestion with statistical machine learning algorithms. These predictive pipelines learn to isolate individual-specific patterns in postprandial response by applying Temporal Convolutional Networks (TCNs) and multi-head self-attention mechanisms. This allows the system to generate highly tailored postprandial glucose curves based on the macronutrient composition of planned meals, enabling more precise pre-meal bolus calculations [27].

3.2. Machine Learning for Clinical Decision Support

3.2.1. Algorithmic Optimization of Basal-Bolus Insulin Systems

For patients on intensive insulin therapy, determining optimal basal rates and insulin-to-carbohydrate ratios (ICRs) is a complex, iterative process [28]. Reinforcement learning (RL) frameworks offer an automated solution to this optimization problem by framing insulin titration as a Markov Decision Process. In this setup, the RL agent receives rewards for maximizing the patient's Time in Range while penalizing episodes of hypoglycaemia. Through continuous interaction with the patient's real-time data stream, the RL algorithm refines its dosing recommendations, suggesting gradual, personalized updates to basal rates and insulin-sensitivity factors. This reduces the cognitive burden on both the clinician and the patient [29].

Table 2. Mathematical and Algorithmic Systems for Better Glycaemic Control

Algorithm/Architecture Class	Core Mathematical/Computational Basis	Clinical Application	Input Variables	Advantage
Long Short-Term Memory (LSTM)	Recurrent gating mechanisms: $f_t = \sigma\left(W_f \cdot [h_{t-1}, x_t] + b_f\right)$	Nocturnal and short-term hypoglycaemia forecasting (60-minute horizon).	Historical CGM values, active insulin on board (IOB), carbohydrate logs.	Captures long-term temporal dependencies in non-linear physiological datasets.
Temporal Convolutional Network (TCN)	Dilated causal 1D convolutions: $(F *_d x)(t) = \sum_{i=0}^{k-1} f(i) \cdot x_{t-d \cdot i}$	Postprandial glucose excursion modeling.	Macronutrient composition (fat, protein, carbohydrates), meal timing, baseline glycemia.	Avoids gradient vanishing issues; processes multi-scale inputs in parallel.
Deep Reinforcement Learning (DRL)	Markov Decision Process (MDP) optimization via Bellman Equation.	Autonomous basal-bolus titration and insulin-to-carbohydrate ratio (ICR) updates.	Real-time glucose trajectories, physical exertion, heart rate variability, sleep stages.	Learns optimal, time-varying metabolic profiles directly through environmental reward feedback.
Model Predictive Control (MPC)	Minimization of cost function: $J = \sum \left(G(t+k) - G_{ref}\right)^2 + \rho\left(\Delta I(t+k)\right)^2$	Closed-loop artificial pancreas pump control algorithms.	Interstitial glucose levels, historical infusion records, subcutaneous absorption kinetics.	Solves constrained optimization problems under strict physiological safety bounds.
Graph Neural Networks (GNN)	Message-passing node updates: $h_v^{(k)} = \text{AGGREGATE}\left(\left\{h_u^{(k-1)} : u \in \mathcal{N}(v)\right\}\right)$	Multi-omic network pharmacology and drug target identification.	Single nucleotide polymorphisms (SNPs), metabolites, gut microbiota operational taxonomic units.	Preserves topological relationships within complex systems biology communication networks.

3.2.2. Data-Driven Classification for Custom Pharmacotherapy Selection

Selecting the most appropriate non-insulin therapeutic agent requires a clear characterization of the patient's primary underlying pathophysiological drivers [30]. Unsupervised machine learning clustering algorithms, such as k-means and hierarchical clustering, can analyze multi-dimensional clinical registries containing fasting C-peptide levels, autoantibody status, age of onset, and body mass index. This approach classifies patients into distinct clusters that reflect different pathophysiological states such as severe insulin-deficient versus severe insulin-resistant phenotypes. Clinicians can then utilize these data-driven classifications to select targeted first-line therapies, choosing insulin-sensitizing SGLT2 inhibitors or GLP-1 receptor agonists for insulin-resistant clusters, and early insulin-replacement methods for C-peptide-deficient cohorts [31].

3.3. Closed-Loop Artificial Pancreas Systems

3.3.1. Model Predictive Control Algorithms in Automated Insulin Delivery

The automated management of type 1 diabetes has been greatly advanced by the development of closed-loop systems, commonly called the artificial pancreas [32]. These systems rely on Model Predictive Control (MPC) algorithms, which use a mathematical model of human metabolic dynamics typically based on the Bergman minimal model or the Cobelli simulation model to predict how future interstitial glucose levels will respond to changes in insulin delivery. The MPC controller solves a constrained optimization problem at every sampling interval, usually every five minutes, adjusting the pump's insulin infusion rate to minimize deviation from a target glucose level while respecting strict physiological safety boundaries to prevent over-delivery of insulin [33].

3.3.2. Adaptability to Real-World Physical Activity and Dietary Inputs

While MPC controllers work well under fasting conditions, unannounced physical activity and meals present major challenges for automated insulin delivery systems [34]. Physical exertion rapidly increases muscle insulin-independent glucose uptake, which can trigger sudden, severe hypoglycaemia if insulin infusion rates are not preemptively reduced. Modern closed-loop systems address this by integrating wearable biometric data such as step counts, triaxial accelerometry, and galvanic skin response directly into the control loop. Adaptive machine learning controllers can temporarily reduce insulin delivery or increase glucose targets during exercise by incorporating these real-time physical activity indicators significantly lowering the risk of exercise-induced hypoglycaemia [35]

4. Precision Medicine and Molecular Stratification

4.1. Multi-Omics Characterization of Metabolic Diversity

4.1.1. Genomic and Epigenomic Mapping of Disease Susceptibility

The genetic landscape of diabetes mellitus involves a complex interplay between monogenic variants and highly polygenic systems [36]. Genome-wide association studies (GWAS) have identified over 500 independent loci associated with type 2 diabetes risk, primarily affecting genes involved in pancreatic β-cell development, insulin processing, and peripheral insulin receptor sensitivity [37]. To translate these genomic discoveries into clinical utility, polygenic risk scores (PRS) are calculated by aggregating the weighted effects of millions of single nucleotide polymorphisms (SNPs) across the genome. This mathematical notation is given by:

$$PRS_i = \sum_{j=1}^{M} \beta_j X_{ij}$$

where PRS_i represents the polygenic risk score for individual i, M is the total number of genetic variants analyzed, β_j represents the log-odds ratio or regression weight of variant j derived from large-scale meta-analyses, and X_{ij} represents the dosage of risk allele j (0, 1, or 2) possessed by the individual. Incorporating PRS into early screening protocols permits the identification of individuals with high lifetime genetic susceptibility before the onset of clinical symptoms, enabling targeted prevention strategies [38].

Beyond inherited genomic variations, epigenetic modifications represent a critical link between environmental exposures such as physical inactivity and high-calorie diets and metabolic dysfunction [39]. DNA methylation patterns, particularly at CpG islands within the promoter regions of insulin-signaling and mitochondrial-biogenesis genes (e.g., PPARGC1A), undergo dynamic alterations in response to metabolic stress. Histone modifications, including the acetylation of H3K9 and the methylation of H3K4, regulate chromatin accessibility, thereby governing the transcriptional activity of pro-inflammatory cytokines in adipose tissue [40]. These epigenetic marks are highly reversible, serving as potential biomarkers for monitoring response to therapeutic interventions and lifestyle modifications.

4.1.2 Transcriptomic, Proteomic, and Metabolomic Biomarkers

While the genome provides a static blueprint of inherited susceptibility, downstream functional omics capture real-time physiological states [41]. High-throughput transcriptomic profiling of peripheral blood mononuclear cells reveals active gene expression networks associated with immune-mediated cellular stress and systemic inflammation, offering insight into early autoimmune insulitis. These transcriptomic alterations correlate directly with changes in the circulating proteome, where multiplexed immunoassays identify specific protein signatures that precede the clinical manifestation of diabetic retinopathy and nephropathy [42]. Notably, elevations in inflammatory proteins such as tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) and intercellular adhesion molecule 1 (ICAM1) serve as reliable early indicators of microvascular deterioration.

Table 3. Multi-Omic Biomarkers and Functional Correlates in Metabolic Pathology

Omic Layer	Biomarker(s)	Functional Role	Clinical Predictive Value
Genomics	Polygenic Risk Score (PRS_i) based on SNPs in SLC30A8, HHEX.	Pancreatic islet development, zinc transport, and glucose-stimulated insulin release.	Quantifies lifetime genetic susceptibility prior to clinical onset.
Epigenomics	DNA methylation of CpG islands in the PPARGC1A promoter region.	Mitochondrial biogenesis dysfunction, skeletal muscle metabolic overload.	Tracks longitudinal cellular response to physical activity and dietary interventions.
Transcriptomics	Peripheral Blood Mononuclear Cell (PBMC) expression of NF-κB targets.	Chronic low-grade systemic vascular inflammation and macrophage activation.	Identifies active, preclinical phases of autoimmune insulitis.
Proteomics	Tumor Necrosis Factor Receptor Superfamily Member 1A (TNFRSF1A), ICAM1.	Endothelial cell adhesion, inflammatory cascade recruitment, and microvascular stress.	Serves as an early diagnostic indicator for diabetic nephropathy and retinopathy.
Metabolomics	Branched-Chain Amino Acids (BCAA: leucine, isoleucine, valine), acylcarnitines.	Impaired tricarboxylic acid (TCA) cycle activity, mitochondrial fatty acid oxidation saturation.	Resolves active transition states of insulin resistance and skeletal muscle lipid accumulation.

Metabolomic profiling using liquid chromatography-mass spectrometry (LC-MS) provides a detailed assessment of cellular metabolism [43]. Individuals progressing toward clinically defined metabolic dysfunction exhibit marked elevations in circulating branched-chain amino acids (BCAAs) specifically leucine, isoleucine, and valine and their catabolic byproducts, short-chain acylcarnitines. High levels of these compounds indicate a state of mitochondrial overload, where chronic overnutrition impairs the metabolic efficiency of the tricarboxylic acid (TCA) cycle within skeletal muscle, causing accumulation of toxic lipid intermediates. Metabolic transition states can be accurately identified by combining these metabolite profiles with clinical records facilitating early intervention before permanent cellular damage occurs [44].

4.2. Subphenotypic Taxonomy of Diabetes

4.2.1. Deconstruction of Type 2 Diabetes Heterogeneity

The traditional diagnostic criteria for type 2 diabetes rely heavily on simple glycaemic thresholds, failing to address the highly variable pathophysiological mechanisms that drive the disease in different patients [45].



Figure 2. Subphenotypic Taxonomy of Adult-Onset Diabetes

To resolve this heterogeneity, cluster analysis algorithms partition patients into distinct biological subphenotypes. Applying unsupervised machine learning models to clinical parameters at diagnosis including age of onset, body mass index (BMI), glycated hemoglobin (HbA_{1c}), homeostatic model assessment of β-cell function (HOMA-β), and homeostatic model assessment of insulin resistance (HOMA-IR) identifies five distinct disease clusters [46]:

- Severe Autoimmune Diabetes (SAID): Characterized by early age of onset, presence of glutamic acid decarboxylase autoantibodies (GADA), low BMI, and absolute insulin deficiency, closely mirroring classic type 1 diabetes.
- Severe Insulin-Deficient Diabetes (SIDD): Distinguished by GADA-negative status, low insulin secretion capacity (low HOMA-β), high HbA_{1c}, and an elevated risk of diabetic retinopathy.
- Severe Insulin-Resistant Diabetes (SIRD): Characterized by severe insulin resistance (high HOMA-IR), elevated BMI, and a significantly higher risk of diabetic kidney disease and non-alcoholic fatty liver disease.
- Mild Obesity-Related Diabetes (MODD): Identified by moderate insulin resistance, elevated BMI, absence of autoimmune markers, and a relatively benign disease progression pathway.
- Mild Age-Related Diabetes (MARD): Characterized by late-onset disease, modest glycaemic alterations, and low complication rates, representing normal age-associated metabolic decline.

This taxonomic refinement enables a more accurate characterization of disease trajectories, shifting metabolic medicine away from speculative, generalized diagnostic labels [47].

Table 4. Biological and Clinical Subphenotypes of Adult-Onset Diabetes Mellitus

Subphenotype Cluster	Diagnostic Criteria	Genetic/Omic Correlates	Secondary Complications	Optimal Targeted Pharmacotherapy
Severe Autoimmune Diabetes (SAID)	GADA positivity, low BMI, rapid insulin deficiency.	High HLA-DQ/DR risk haplotypes; autoimmune transcription profiles.	Rapid progression to absolute insulin dependence; ketoacidosis risk.	Early, intensive basal-bolus insulin regimens.
Severe Insulin-Deficient Diabetes (SIDD)	GADA negativity, low HOMA-β (diminished secretion), high baseline HbA_{1c}.	Loci linked to β-cell function/mass (e.g., TCF7L2, KCNQ1).	High incidence of diabetic retinopathy and early neuropathy.	Early insulin therapy; glucagon-like peptide-1 (GLP-1) receptor agonists.
Severe Insulin-Resistant Diabetes (SIRD)	High HOMA-IR (severe resistance), elevated BMI, marked hyperinsulinemia.	Loci linked to adipocyte differentiation and lipid storage (e.g., PPARG).	Diabetic kidney disease (DKD); non-alcoholic fatty liver disease (NAFLD).	Sodium-glucose cotransporter-2 (SGLT2) inhibitors; metformin; thiazolidinediones.
Mild Obesity-Related Diabetes (MODD)	Elevated BMI, moderate insulin resistance, absence of autoimmune markers.	Polygenic obesity risk architectures (e.g., FTO, MC4R).	Relatively low microvascular risk; progressive macrovascular complications.	GLP-1 receptor agonists; structured metabolic surgery; intensive lifestyle interventions.
Mild Age-Related Diabetes (MARD)	Late-onset (>60 years), modest glycaemic alterations, low HOMA-IR.	Loci associated with age-related functional decline of tissue sensitivity.	Low progression rate; slow-onset macrovascular pathology.	Monotherapy (e.g., metformin) or conservative step-wise oral agents.

4.2.2 Clinical Adaptation of Cluster-Specific Pharmacotherapy

Classifying patients into these biological clusters allows for the targeted selection of pharmacotherapies based on specific underlying pathophysiological pathways [48]. In the SIRD subphenotype, where hepatic insulin resistance and systemic inflammation predominate, standard treatment utilizing insulin secretagogues is often ineffective and may accelerate β-cell exhaustion. Instead, these patients derive greater therapeutic benefit from sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, which reduce cardiovascular risk and slow the progression of diabetic nephropathy [49].

Conversely, individuals classified within the SIDD cluster, where insulin secretion is impaired, require early, proactive basal-bolus insulin regimens or insulin secretagogues to prevent rapid glycaemic deterioration [50]. For patients in the MODD cluster, where lifestyle-induced metabolic overload is the primary driver, clinical management focuses on metabolic surgery, structured dietary weight-loss programs, and GLP-1 receptor agonist therapies to optimize body mass and improve insulin sensitivity. This structured allocation of therapeutic agents minimizes trial-and-error prescribing, shortens the time required to achieve target glycaemic control, and reduces medication-related adverse events [51].

5. Digital Health Ecosystems and Wearable Technologies

5.1. Sensing Infrastructure and Drug Delivery Integration

5.1.1. High-Frequency Continuous Glucose Monitoring

The widespread deployment of continuous glucose monitoring (CGM) systems represents a major milestone in modern diabetes management [52]. These devices use subcutaneous electrochemical or optical biosensors to measure interstitial fluid glucose concentration at high frequencies, typically every 1 to 5 minutes. Because glucose must diffuse from the intravascular space into the interstitial fluid, a physiological lag time exists, typically modeled as a first-order linear system:

$$\tau \frac{dG_{IG}(t)}{dt} = G_{BG}(t) - G_{IG}(t)$$

where $G_{BG}(t)$ represents blood glucose concentration at time t, $G_{IG}(t)$ is the interstitial glucose concentration, and τ is the characteristic system lag constant (typically ranging from 5 to 15 minutes). Advanced machine learning algorithms run on the receiver device to correct for this lag dynamically, ensuring that real-time readings reflect current blood glucose levels accurately [53].

CGM metrics have expanded clinical assessment parameters beyond static HbA_{1c} measurements [54]. The clinical standard now emphasizes Time in Range (TIR), defined as the percentage of time spent within the target glycaemic window of 70 mg/dL to 180 mg/dL (3.9 mmol/L to 10.0 mmol/L). Clinical validation studies show that every 10% reduction in TIR correlates with a proportional increase in the risk of microalbuminuria and diabetic retinopathy. This strong association establishes TIR as a primary outcome metric for evaluating both pharmaceutical and digital therapeutic interventions [55].

5.1.2. Smart Insulin Delivery and Connected Platforms

To complement continuous sensing, smart insulin pens and connected infusion systems capture precise, real-time insulin administration data [56]. Smart insulin pens record the exact timestamp and dose volume of every bolus and basal injection, transmitting these parameters via low-energy wireless protocols to a central mobile application. These connected systems run algorithms that calculate "active insulin on board" (IOB), preventing cumulative dose-stacking a common cause of severe, unpredictable hypoglycaemia. Integrating real-time subcutaneous delivery data with continuous glucose readings provides clinicians with an objective view of patient adherence and individual dose-response curves [57].

5.2. Interoperability and Remote Clinical Monitoring

5.2.1. Cloud-Based Data Aggregation and Interoperable APIs

The clinical utility of wearable sensors and smart injectors relies on their integration into unified, interoperable digital systems [58]. Historically, medical device data existed within closed proprietary ecosystems, preventing comprehensive clinical analysis. Modern digital health platforms overcome this barrier by utilizing secure, standardized Application Programming Interfaces (APIs) built on the Fast Healthcare Interoperability Resources (FHIR) framework. This structural standardization permits the automated extraction, transformation, and loading of high-frequency sensor streams, physical activity data, and clinical laboratory metrics into a unified patient record [59].

5.2.2. Virtualized Care Systems and Remote Clinical Monitoring

Combining continuous data streams into electronic health records (EHRs) enables the virtualization of diabetes care [60]. Rather than waiting for quarterly clinical visits, care teams use automated triage dashboards that scan the patient population to identify individuals experiencing high glycaemic variability or frequent hypoglycaemic events. Remote patient monitoring systems generate automated, prioritize alerts based on predefined physiological thresholds, prompting clinical staff to initiate early teleconsultations. This remote, proactive approach significantly reduces diabetes-related hospitalization rates, improves patient safety, and expands high-quality care access to rural and underserved populations [61].

6. Systems Biology and Network-Based Modeling

6.1. Multi-Organ Metabolic Modeling

6.1.1. In Silico Modeling of Pancreatic β-cell Secretory Dynamics

A core focus of systems biology in diabetes is the mathematical representation of pancreatic β-cell secretory dynamics [62]. Standard physiological models represent insulin secretion as a biphasic process in response to glucose stimulation. This includes a rapid, transient first phase representing the fusion of pre-docked insulin secretory granules, followed by a sustained, slowly rising second phase involving the recruitment of reserve-pool granules. This secretory kinetic architecture can be mathematically formalized using a system of ordinary differential equations (ODEs):

$$\frac{dI_p(t)}{dt} = -k_e I_p(t) + \sigma\big(G_{BG}(t)\big)$$

$$\sigma(G_{BG}) = \frac{V_{max} G_{BG}^n}{K_m^n + G_{BG}^n}$$

where $I_p(t)$ represents plasma insulin concentration, k_e is the systemic elimination rate constant of insulin, and $\sigma\big(G_{BG}(t)\big)$ represents the insulin secretion rate as a non-linear Hill function of blood glucose concentration [63]. In this equation, V_{max} is the maximum secretory capacity of the β-cells, K_m represents the glucose concentration at half-maximal activation, and n is the Hill cooperativity coefficient. Simulating these ODEs in silico allows researchers to model progression rates of β-cell functional decline under varying conditions of chronic glucotoxicity and lipotoxicity.

6.1.2. Mathematical Formulation of Inter-Organ Glucose Homeostasis

Extending single-organ models, comprehensive compartmental designs represent glucose and insulin dynamics across the major metabolic organs, including the liver, skeletal muscle, brain, kidneys, and adipose tissue [64]. A widely utilized system is the minimal model of glucose kinetics, which describes the clearance of glucose from the plasma space through both insulin-independent mechanisms and insulin-dependent pathways:

$$\frac{dG(t)}{dt} = -\big(S_G + X(t)\big)G(t) + S_G G_b + \frac{Ra(t)}{V_I}$$

$$\frac{dX(t)}{dt} = -p_2 X(t) + p_3\big(I(t) - I_b\big)$$

$$\frac{dI(t)}{dt} = -nI(t) + \gamma\big(G(t) - h\big)t$$

In this system, G(t) represents plasma glucose concentration, X(t) is the activity of insulin in a remote interstitial compartment, and I(t) represents plasma insulin concentration [65]. The parameter S_G represents glucose effectiveness (the ability of glucose to accelerate its own disposal independent of insulin), G_b and I_b are baseline glucose and insulin concentrations, Ra(t) is the rate of appearance of exogenous glucose, V_I is the volume of distribution of glucose, p_2 and p_3 are rate constants governing insulin action, n is the systemic insulin clearance rate, and γ and h represent parameters governing pancreatic insulin release. Integrating these equations into digital twins allows clinical systems to simulate patient-specific metabolic responses to virtual therapeutic adjustments, providing an objective tool for treatment optimization [66].



Figure 3. The Bergman Minimal Model of Metabolic Fluxes

6.2. Network-Based Medicine and Dynamic Pathophysiology

6.2.1. Computational Reconstruction of Gut-Brain-Immune Communications

Modern systems biology views diabetes as an emergent state arising from complex communication networks between the gastrointestinal tract, central nervous system, and immune apparatus [67]. The gut microbiota influences host insulin sensitivity through the production of bioactive short-chain fatty acids (SCFAs), such as butyrate and propionate. These SCFAs activate G-protein coupled receptors (GPR41 and GPR43) on enteroendocrine L-cells, stimulating the secretion of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This endocrine signaling pathway modulates vagal afferent nerves, which transmit signals to the hypothalamus to regulate hepatic glucose output and satiety [68].

Concurrently, metabolic overload triggers a low-grade, systemic inflammatory response within adipose tissue [69]. Hypertrophic adipocytes experience local hypoxia, initiating the secretion of pro-inflammatory chemokines, particularly monocyte chemoattractant protein-1 (MCP-1). This signal recruits pro-inflammatory M1 macrophages to the stromal vascular fraction of adipose tissue, leading to high local concentrations of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Computational network models map these complex cellular interactions, illustrating how inflammatory signaling networks impair insulin sensitivity globally [70].

6.2.2. Cellular Signaling Cascade Network Mapping

At the cellular level, insulin resistance is characterized by a series of signaling failures within insulin-sensitive tissues [71]. Under normal physiological conditions, insulin binding to the extracellular α -subunits of the insulin receptor (IR) induces transphosphorylation of its intracellular β-subunits. This activation initiates a signaling cascade, recruiting and phosphorylating insulin receptor substrate (IRS) proteins, particularly IRS-1 and IRS-2, on tyrosine residues. Phosphorylated IRS then binds and activates phosphoinositide 3-kinase (PI3K), which converts phosphatidylinositol 4,5-bisphosphate (PIP_2) to phosphatidylinositol 3,4,5-trisphosphate (PIP_3). This lipid second messenger recruits and activates phosphoinositide-dependent kinase-1 (PDK1), which subsequently phosphorylates and activates the serine/threonine kinase Akt, as illustrated below:

$$\text{Insulin} + \text{IR} \longrightarrow \text{p-IR} \longrightarrow \text{p-IRS-1} \longrightarrow \text{PI3K Activation} \longrightarrow \text{PIP}_3 \longrightarrow \text{p-Akt} \longrightarrow \text{GLUT4 Translocation}$$

Activated Akt drives several downstream metabolic actions, including the translocation of glucose transporter 4 (GLUT4) vesicles to the plasma membrane to facilitate glucose uptake into skeletal muscle and adipose cells [72].

In insulin-resistant states, chronic nutrient excess and elevated intracellular lipid intermediates specifically diacylglycerols and ceramides activate stress-activated protein kinases, including c-Jun N-terminal kinase (JNK) and inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-β) [73]. These kinases phosphorylate IRS-1 on specific serine residues (such as Ser307), disrupting the physical interaction between IRS-1 and the insulin receptor, and preventing downstream PI3K/Akt activation. Mapping these intracellular signaling networks using mathematical models helps identify specific molecular nodes that can be targeted by small-molecule drugs to restore insulin sensitivity [74]



Figure 4. Intracellular Insulin Receptor Signaling Cascade and Resistance Nodes

7. Critical Appraisal and Challenges

7.1. Algorithmic Bias and Clinical Disparities in Predictive Modeling

Despite the analytical and clinical promises of machine learning pipelines in metabolic medicine, their deployment introduces significant challenges that threaten equitable care delivery. Algorithmic bias represents a primary vulnerability, stemming from the demographic and clinical homogeneity of the cohorts used to train predictive architectures [75]. The vast majority of continuous glucose monitoring datasets and biometric repositories are derived from high-income populations with reliable access to advanced health technologies. When deep learning models trained on these resource-rich cohorts are applied to patients from socioeconomically disadvantaged backgrounds or low-and-middle-income countries, their predictive accuracy drops significantly [76]. This drop occurs because standard algorithms fail to account for distinct dietary patterns, structural barriers to medication adherence, or highly variable access to stable nutrition.

The conceptual baseline of digital health integration highlights how unstructured, historically fragmented data struggle to represent diverse patient experiences fairly. This limitation leads to systemic errors when predictive models assume uniform physiological or behavioral patterns across all socio-demographic bands. Genetic variations and clinical profiles differ substantially across ethnic groups, meaning that polygenic risk scores and cluster-analysis taxonomies calculated using Northern European cohorts cannot be reliably generalized to East Asian, South Asian, or African populations without extensive localized recalibration [77]. This lack of generalizability risks perpetuating clinical disparities, as minority populations may receive inaccurate risk predictions or inappropriate therapeutic selections from clinical decision support systems [78].

7.2. Regulatory Guidelines and Computational Validation

The translation of predictive machine learning models and closed-loop insulin delivery controllers from experimental settings to clinical environments is governed by strict regulatory processes. The United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) classify adaptive medical software as Software as a Medical Device (SaMD) [79]. This regulatory classification requires rigorous validation to prove that an algorithm is both safe and effective before it can be used in patient care. For static, non-adaptive algorithms, conventional verification involves testing on historical datasets to evaluate accuracy, sensitivity, and specificity. However, for continuously adaptive models such as reinforcement learning systems that dynamically update basal-bolus recommendations standard validation protocols are insufficient.

Because these models update their parameters in response to real-time clinical data, they can exhibit unpredictable behavioral drifts when exposed to unusual clinical scenarios, such as acute infectious illness, trauma, or unexpected dietary modifications [80]. Regulatory agencies are developing new adaptive clearance pathways that require continuous post-market surveillance and real-time safety bounds. Computational systems must also undergo extensive in silico validation using validated metabolic simulators, such as the UVA/Padova type 1 diabetes metabolic simulator, before starting human clinical trials [81]. This simulation testing ensures that when the controller is exposed to extreme noise, sensor dropouts, or sudden carbohydrate loads, it remains within safe physiological limits, avoiding life-threatening hypoglycaemia.

7.3. Cybersecurity, Data Governance, and Privacy in Distributed Networks

The shift toward cloud-based digital health ecosystems and connected physical delivery devices introduces serious cybersecurity risks. Modern diabetes monitoring systems rely on telemetry networks that link subcutaneous sensors, smart insulin pens, infusion pumps, mobile applications, and clinical dashboards via low-energy wireless protocols and cloud-based application programming interfaces [82]. This complex, distributed network creates several potential entry points for cyber-attacks. Malicious actors could intercept telemetry streams to access sensitive patient health information, or worse, perform unauthorized remote dosing commands on an insulin pump, presenting a direct physical threat to the patient [83].

Table 5. Technical Challenges and Mitigation Measures in Implementing Digital Twin

Computational Challenge	**Operational Barrier**	**Mitigation Measure**	**Regulatory Standard**
Algorithmic Demographic Bias	Drops in predictive accuracy when models are applied to racially, behaviorally, or socioeconomically diverse patient cohorts.	Localized algorithmic recalibration; synthetic data generation; multi-ethnic biobanking.	BePRECISE reporting guidelines [95]; Consolidated Standards of Reporting Trials (CONSORT-AI) [80].
Behavioral Model Drift	Real-time deviations in predictive performance when exposed to unexpected physical stress, illnesses, or dietary changes.	Continuous post-market surveillance; execution of adaptive clearance pathways; in silico simulator validation.	FDA Software as a Medical Device (SaMD) Pre-Cert Program [79]; UVA/Padova Metabolic Simulators [81].
Telemetry Vulnerability	Unauthorized access, data interception, or malicious dosing commands across distributed wearable device ecosystems.	Cryptographic wireless transport; hardware-level root-of-trust; end-to-end telemetry encryption.	Medical Device Cybersecurity Regulatory Science standards (FDA/ISO) [82].
Data Silos & Fragmentation	Heterogeneous data formats stored in proprietary manufacturer clouds, hindering unified analytical pipeline ingestion.	Standardized data mapping; automated extraction, transformation, and loading (ETL) pipelines.	HL7 Fast Healthcare Interoperability Resources (FHIR) [59].
Privacy Loss in Distributed Training	Reversal-engineering risks of raw patient clinical datasets from global machine learning parameters.	Decentralized parameter training on edge devices combined with intentional mathematical noise injection.	Federated Learning frameworks [84] combined with Local Differential Privacy (LDP) algorithms.

To mitigate these risks, next-generation diabetes platforms are adopting decentralized data and advanced encryption standards. Federated learning has emerged as a promising approach to train predictive machine learning models without directly centralizing raw patient data [84]. Under federated guidelines, the global algorithm is distributed to individual edge devices (e.g., patient smartphones), where model parameters are updated locally using the patient's real-time data. These updated parameters rather than the raw data itself are then transmitted back to a central server, where they are aggregated to refine the global model. To protect patient privacy further, differential privacy algorithms introduce mathematical noise to the local parameter updates, ensuring that individual clinical records cannot be reverse-engineered from the global model.

8. Further Scope and Clinical Applications

8.1. Autonomous Multi-Loop Closed-Loop Systems

While current automated insulin delivery platforms have significantly improved glycaemic outcomes, they remain single-hormone systems focused solely on insulin infusion. Future systems are moving toward multi-hormone, multi-loop closed-loop systems that replicate pancreatic endocrine function more closely [85]. Integrating glucagon delivery into the automated control loop provides an active physiological defense against hypoglycaemia, allowing the system to handle unexpected physical exertion or delayed carbohydrate absorption more safely. Additionally, co-formulations of insulin with amylin analogs, such as pramlintide, are being integrated into automated algorithms to slow gastric emptying and suppress postprandial glucagon secretion, reducing the glycemic spike that follows high-carbohydrate meals [86].

On the algorithmic side, the next generation of closed-loop systems will transition from standard model predictive control to fully adaptive deep reinforcement learning architectures [87]. Unlike traditional controllers that rely on rigid, pre-defined models of human metabolism, deep reinforcement learning agents can learn personalized, time-varying metabolic profiles directly from continuous clinical inputs. These systems can dynamically adjust to changes in insulin sensitivity, hormonal shifts, and behavioral patterns without requiring manual clinical recalibration. This transition will make insulin delivery fully autonomous, eliminating the need for patients to announce meals or log exercise manually.

8.2. Longitudinal Multi-Omic Profiling and Knowledge Graph

To achieve true precision medicine, future digital twins must move beyond simple biometric streams to integrate deep, longitudinal molecular profiles. This integration involves supplementing high-frequency CGM and physical activity data with periodic, multi-omic updates, including epigenomic marks, circulating proteomic profiles, and gut metagenomic sequences [88]. Integrating these heterogeneous, multi-scale data streams requires advanced computational structures capable of mapping complex biological relationships over time.

Knowledge graphs provide a robust framework to organize this diverse information [89]. Knowledge graphs clarify the underlying drivers of metabolic dysfunction by representing biological entities such as SNPs, bacterial taxa, serum metabolites, and clinical symptoms as nodes, and their functional interactions as directed edges. Graph Neural Networks (GNNs) can then analyze these networks to identify novel biomarkers and predict how specific subphenotypes will respond to targeted pharmacotherapies. This approach allows clinical systems to transition from managing clinical symptoms to correcting the underlying molecular pathways of the disease [90].



Figure 5. GNN-Based Multi-Omics Knowledge Graph and Therapeutic Prediction

8.3. Human-in-the-Loop Clinician Interfaces and Shared Decision-Making

As artificial intelligence models become more complex, their clinical adoption depends heavily on their interpretability. The clinical community is rightfully hesitant to accept treatment recommendations from "black box" deep learning models that do not provide clear clinical reasoning. To bridge this gap, future clinical decision support systems must utilize Explainable Artificial Intelligence (XAI) frameworks, such as SHapley Additive exPlanations (SHAP) and Local Interpretable Model-agnostic Explanations (LIME) [91]. These computational techniques translate complex neural network predictions into clear, visual explanations that highlight which patient factors such as recent sleep deprivation, an elevated polygenic risk score, or a specific dietary pattern most heavily influenced a given recommendation.

Utilization of these explainable models into intuitive, clinician-facing dashboards promotes collaborative, shared decision-making [92]. Instead of replacing clinical judgment, these AI-driven systems act as intelligent assistants, presenting personalized therapeutic options alongside clear, evidence-based explanations. This design allows care teams to evaluate model recommendations critically, combine computational insights with their own clinical experience, and adapt therapies to align with the patient’s preferences and lifestyle [93].

9. Conclusion

The clinical management of diabetes mellitus is undergoing a fundamental transformation, shifting metabolic medicine from a historic, reactive discipline to a proactive, predictive, and system-level science. The historical reliance on static, retrospective clinical markers is being replaced by real-time physiological tracking and multi-scale biological characterization. Computational systems can now resolve the substantial biological heterogeneity that has long limited the effectiveness of standardized by combining high-frequency biometric streams from wearable sensors with deep multi-omic and population-level care algorithms.

This transition is realized through clinical frameworks that connect advanced machine learning algorithms, automated closed-loop delivery platforms, and metabolic digital twins. These integrated systems do not merely automate routine clinical tasks; they provide a continuous, adaptive regulatory loop that anticipates glycaemic fluctuations, maps individual metabolic trajectories, and matches therapies to specific physiological subphenotypes. As these technologies mature, they will continue to minimize the occurrence of acute glycaemic excursions and slow the progression of chronic microvascular and macrovascular complications, establishing a new clinical standard.

However, realizing the full potential of precision diabetology requires addressing several key systemic challenges. The medical community must work to eliminate algorithmic biases, establish standardized regulatory pathways for adaptive clinical software, and deploy secure, interoperable data architectures that protect patient privacy. Overcoming these barriers through collaborative, cross-disciplinary efforts will ensure these computational innovations can be deployed equitably and safely. Unifying computational intelligence with systems biology offers a clear path toward a scalable, data-driven, and highly personalized approach to metabolic health worldwide.

References

[1] American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321.

[2] Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Global epidemiology of type 2 diabetes present and future perspectives. Cureus. 2020;12(4):e7663.

[3] Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):2017-2066.

[4] Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.

[5] Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: how HbA1c can mislead. J Diabetes Sci Technol. 2019;13(4):761-766.

[6] Monnier L, Colette C, Owens DR. Glycaemic variability: the third component of the dysglycaemic triad in type 2 diabetes. Diabetes Metab. 2018;44(6):486-493.

[7] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.

[8] Lee J, Kim J, MH, et al. Digital health platforms in chronic disease management: a systematic review. NPJ Digit Med. 2021;4(1):82.

[9] Beam AL, Kohane IS. Big data and machine learning in health care. JAMA. 2018;319(13):1317-1318.

[10] Franks PW, McCarthy MI. Exposing the clinical and biological heterogeneity of type 2 diabetes. Lancet Diabetes Endocrinol. 2016;4(8):637-638.

[11] Kitano H. Systems biology: a brief overview. Science. 2002;295(5560):1662-1664.

[12] Shamanna P, Saboo B, Damodharan S, et al. Whole-body digital twin technology for precision regulation and remission of type 2 diabetes: a randomized controlled trial. Diagnostics. 2021;11(11):2076.

[13] Khunti K, Wolden ML, Thorsted BL, Carrasco B, Pratley RE. Clinical inertia in starting insulin therapy in patients with type 2 diabetes. Diabetes Care. 2013;36(11):3411-3417.

[14] Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care. 2015;38(1):140-149.

[15] Wright LA, Hirsch IB. Metrics of glycaemic control: beyond HbA1c. Clin Chem. 2017;63(11):1676-1681.

[16] Chow E, Bernjak A, Williams S, et al. Risk of cardiac arrhythmias during nocturnal hypoglycaemia in patients with type 2 diabetes: a continuous electrocardiographic monitoring study. Diabetes Care. 2014;37(6):1685-1693.

[17] American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81-S90.

[18] Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221-228.

[19] Dunn J, Runge R, Snyder M. Wearables and the medical revolution. Nat Rev Mater. 2018;3(5):1-4.

[20] Bergenstal RM, Klonoff DC, Cole CH, et al. Closed-loop insulin delivery for type 1 diabetes: a multicenter randomized trial. N Engl J Med. 2016;375(23):2243-2252.

[21] Klonoff DC, Wang J, Rodbard DM, et al. A review of emergent technologies for continuous glucose monitoring. J Diabetes Sci Technol. 2018;12(2):377-389.

[22] Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603.

[23] Gonder-Frederick LA, Grabman JH, Shepard JA, et al. Fear of hypoglycaemia in triage decisions. Diabetes Technol Ther. 2017;19(11):625-633.

[24] Hochreiter S, Schmidhuber J. Long short-term memory. Neural Comput. 1997;9(8):1735-1780.

[25] Zhang Y, Li J, Jiao Y, et al. Predictive modeling of nocturnal hypoglycaemia using deep recurrent neural networks on continuous glucose monitoring data. Diabetes Technol Ther. 2020;22(5):361-370.

[26] Cobelli C, Dalla Man C, Sparacino G, et al. Models of the glucose-insulin system: an overview. Biomed Eng Online. 2009;8(1):35.

[27] Bunescu R, Struble N, Marling C, et al. A temporal convolutional network framework for postprandial glucose forecasting in patients with type 1 diabetes. Comput Biol Med. 2021;130:104212.

[28] Hirsch IB. Intensive insulin therapy in type 1 diabetes mellitus. N Engl J Med. 2005;352(17):1741-1750.

[29] Tejedor M, Woldaregay AZ, Albers D, et al. Reinforcement learning for personalized insulin dosing in type 1 diabetes: a systematic review of clinical feasibility. Artificial Intelligence in Medicine. 2020;104:101832.

[30] Dennis JM. Individualizing therapy in type 2 diabetes: new insights from clinical registries. Diabetologia. 2020;63(12):2511-2517.

[31] Pearson ER. Personalized medicine in diabetes: the road ahead. Diabetologia. 2019;62(10):1778-1785.

[32] Bekiari E, Kitsios K, Thabit H, et al. Artificial pancreas systems for type 1 diabetes: a systematic review and meta-analysis of outpatient trials. BMJ. 2018;361:k1310.

[33] Roman Y, Hovorka R. Model predictive control in closed-loop artificial pancreas systems. Control Eng Pract. 2019;84:102-111.

[34] Riddell MC, Gallen IW, Smart CE, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol. 2017;5(5):377-390.

[35] Jacobs PG, Resalat N, El Youssef J, et al. Incorporating physical activity into model predictive control algorithms for dual-hormone artificial pancreas systems. IEEE Trans Biomed Eng. 2018;65(3):503-512.

[36] Fuchsberger C, Flannick J, Teslovich TM, et al. The genetic architecture of type 2 diabetes. Nature. 2016;536(7614):41-47.

[37] Mahajan A, Taliun D, Sabater-Lleal M, et al. Fine-mapping global somatometric and metabolic traits identifies 500 novel loci. Nat Genet. 2018;50(11):1505-1513.

[38] Khera AV, Chaffin M, Wade KH, et al. Polygenic prediction of type 2 diabetes risk in diverse populations. JAMA. 2018;320(14):1458-1468.

[39] Ling C, Rönn T. Epigenetics in human obesity and type 2 diabetes. Cell Metab. 2019;29(5):1028-1044.

[40] Volkov P, Bacos K, Ofori JK, et al. Whole-genome bisulfite sequencing of human pancreatic islets reveals novel differentially methylated regions in type 2 diabetes. Diabetes. 2017;66(4):1074-1085.

[41] Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.

[42] Jenkins AJ, Joglekar MV, Januszewski AS, et al. Circulating microRNAs and proteomic biomarkers associated with microvascular complications in type 1 diabetes. Lancet Diabetes Endocrinol. 2019;7(4):280-291.

[43] Newgard CB. Metabolomics and metabolic diseases: where do we stand? Cell Metab. 2017;25(1):43-56.

[44] Wang-Sattler R, Yu Z, Herder C, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8(1):615.

[45] Tuomi T, Santoro N, Caprio S, et al. The many faces of diabetes: a disease of metabolic heterogeneity. Lancet. 2014;383(9922):1084-1093.

[46] Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361-372.

[47] Zaharia OP, Strassburger K, Strom A, et al. Risk of microvascular and macrovascular complications in adult-onset diabetes subgroups: a cohort study. Lancet Diabetes Endocrinol. 2019;7(9):684-694.

[48] Prattichizzo F, de Candia P, Ceriello A. Moving from clinical subgroups of type 2 diabetes to cluster-specific pharmacotherapy. Lancet Diabetes Endocrinol. 2018;6(12):917-919.

[49] Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39.

[50] Misra S, Shields B, Colclough K, et al. South Asian and African-Caribbean patients diagnosed with type 2 diabetes: clinical subgroups and outcomes. Diabetologia. 2020;63(11):2345-2354.

[51] Schloot NC, Haupt F, Al-Hassany L, et al. Clustering of type 2 diabetes patients: clinical utility and future horizons. Front Endocrinol. 2021;12:670985.

[52] Beck RW, Riddlesworth T, Anderson K, et al. Effect of continuous glucose monitoring on glycaemic control in adults with type 1 diabetes: the DIAMOND randomized clinical trial. JAMA. 2017;317(4):371-378.

[53] Facchinetti A, Sparacino G, Cobelli C. Modeling the interstitial-to-plasma glucose relation from continuous glucose monitoring data. IEEE Trans Biomedical Eng. 2017;64(9):2013-2020.

[54] Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631-1640.

[55] Beck RW, Limoy T, Bergenstal RM, et al. Association of time in range with the risk of microvascular complications in type 2 diabetes. Diabetes Care. 2019;42(3):400-405.

[56] Heinemann L, Quick O. Smart insulin pens: a major step toward standard clinical adoption. Journal of Diabetes Science and Technology. 2018;12(3):573-581.

[57] Adolfsson P, Hartvigsen C, Kaas A, et al. Integrating connected insulin pens with continuous glucose monitoring to improve clinical outcomes in daily practice. Diabetes Technol Ther. 2020;22(11):812-820.

[58] Klonoff DC, Kerr D. Overcoming barrier ecosystems: interoperability in diabetes technology. J Diabetes Sci Technol. 2018;12(1):3-6.

[59] Mandel JC, Kreda DA, Mandl KD, et al. SMART on FHIR: a standards-based, interoperable apps platform for electronic health records. Journal of the American Medical Informatics Association. 2016;23(5):899-908.

[60] Cahn A, Melzer-Cohen I, Karasik A, et al. Telemedicine-based virtual clinics for diabetes management: clinical efficacy and patient satisfaction. Lancet Diabetes Endocrinol. 2020;8(6):480-482.

[61] Tchero H, Kangambega P, Briand C, et al. Clinical effectiveness of telemedicine in diabetes management: a systematic review and meta-analysis. Telemed J E Health. 2019;25(7):569-583.

[62] Gilon P, Chae HY, Rutter GA, et al. Calcium signaling in pancreatic β-cells: a systems approach. Cell Calcium. 2014;56(5):340-361.

[63] Topp B, Promislow K, deVries G, et al. A model of β-cell mass, insulin, and glucose kinetics: pathways to type 2 diabetes. J Theor Biol. 2000;206(4):605-619.

[64] Dalla Man C, Rizza RA, Cobelli C. Meal simulation model of the glucose-insulin system. IEEE Trans Biomed Eng. 2007;54(10):1740-1749.

[65] Bergman RN, Ider YZ, Bowden CR, et al. Quantitative estimation of insulin sensitivity. Am J Physiol. 1979;236(6):E667-E677.

[66] Corral-Acero J, Margara F, Marciniak M, et al. The medical digital twin: an emerging concept in cardiovascular and metabolic medicine. Eur Heart J. 2020;41(47):4476-4484.

[67] Cani PD, Jordan BF. Gut microbiota, G-protein coupled receptors, and metabolic homeostasis. Nat Rev Endocrinol. 2018;14(12):715-722.

[68] Bagger JI, Knop FK, Holst JJ, et al. The enteroendocrine gut-brain-immune axis in type 2 diabetes: a systems perspective. Lancet Diabetes Endocrinol. 2016;4(5):420-431.

[69] Hotamisligil GS. Inflammation, metaflammation, and immunometabolic disorders. Nature. 2017;542(7640):177-185.

[70] Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127(1):1-4.

[71] Haeusler RA, McGraw TE, Accili D. Biochemical and cellular mechanisms of insulin resistance. Nat Rev Mol Cell Biol. 2018;19(1):31-51.

[72] Leto D, Saltiel AR. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat Rev Mol Cell Biol. 2012;13(6):383-396.

[73] Copps KD, White MF. Regulation of insulin sensitivity by IRS phosphorylation cascades. Diabetologia. 2012;55(9):2565-2582.

[74] Cedersund G, Roll J, Ulriksson A, et al. System-level mathematical modeling of the insulin signaling cascade in human adipocytes. J Biol Chem. 2008;283(18):12257-12267.

[75] Char DS, Shah NH, Magnus D. Implementing machine learning in health care addressing ethical challenges. N Engl J Med. 2018;378(11):981-983.

[76] Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347-1358.

[77] Martin AR, Kanai M, Kamatani Y, et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584-591.

[78] Vyas DA, Eisenstein LG, Jones DS. Misrepresenting race the limits of clinical algorithms. N Engl J Med. 2020;383(9):874-882.

[79] Shuren J, Patel B, Gottlieb S. FDA regulation of mobile medical apps. JAMA. 2018;320(4):337-338.

[80] Liu X, Rivera SC, Moher D, et al. Reporting guidelines for clinical trials evaluating artificial intelligence interventions: the CONSORT-AI extension. Nat Med. 2020;26(9):1364-1374.

[81] Kovatchev BP, Breton M, Man CD, et al. In silico preclinical trials: a methodology to replace animal testing in closed-loop development. IEEE Trans Biomed Eng. 2009;56(5):1258-1266.

[82] Klonoff DC. Cybersecurity for connected medical devices in diabetes. J Diabetes Sci Technol. 2017;11(1):3-5.

[83] Radcliffe J. Hacking medical devices: security vulnerabilities in wireless insulin pumps. Black Hat Technical Conference. 2011;12:22-29.

[84] Rieke N, Hancox J, Li W, et al. The future of digital health with federated learning. NPJ Digit Med. 2020;3(1):119.

[85] Haidar A, Legault L, Messier V, et al. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for type 1 diabetes: an open-label randomised controlled trial. Lancet Diabetes Endocrinol. 2015;3(1):17-26.

[86] Riddle MC, Youssef JE, El-Hassany Y, et al. Co-administration of pramlintide and insulin in closed-loop architectures: physiological and clinical outcomes. Diabetes Care. 2018;41(7):1470-1478.

[87] Zhu T, Li K, Herrero P, Georgiou P. Deep reinforcement learning for personalized insulin dosing in type 1 diabetes. IEEE Trans Ind Inf. 2020;16(5):3299-3309.

[88] Karczewski KJ, Snyder MP. Integrative omics for health and disease. Nat Rev Genet. 2018;19(5):299-310.

[89] Nicholson JN, Greene CS. Constructing knowledge graphs for systems medicine. Bioinformatics. 2020;36(8):2400-2408.

[90] Hamilton WL, Ying R, Leskovec J. Representation learning on graphs: methods and applications. IEEE Data Eng Bull. 2017;40(3):52-74.

[91] Lundberg SM, Lee SI. A unified approach to interpreting model predictions. Adv Neural Inf Process Syst. 2017;30:4765-4774.

[92] Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361-1367.

[93] Tobias DK, Merino J, Maruthur NM, et al. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med. 2023;29(10):2438-2457.